Overview

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
ALZA
Treatments:
Amifostine
Cytarabine
Topotecan